S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NYSE:EW

Edwards Lifesciences - EW Stock Forecast, Price & News

$82.12
-2.39 (-2.83%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$81.39
$84.14
50-Day Range
$72.27
$84.51
52-Week Range
$67.13
$131.10
Volume
4.74 million shs
Average Volume
3.34 million shs
Market Capitalization
$50.77 billion
P/E Ratio
33.66
Dividend Yield
N/A
Price Target
$89.74

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
9.3% Upside
$89.74 Price Target
Short Interest
Healthy
2.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.28mentions of Edwards Lifesciences in the last 14 days
Based on 44 Articles This Week
Insider Trading
Selling Shares
$6.93 M Sold Last Quarter
Proj. Earnings Growth
12.70%
From $2.52 to $2.84 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

84th out of 1,028 stocks

Surgical Appliances & Supplies Industry

5th out of 23 stocks

EW stock logo

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Edwards Lifesciences (NYSE:EW) Cut to "Neutral" at Piper Sandler
Edwards Lifesciences Corp. Q4 Profit Increases, beats estimates
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Company Calendar

Last Earnings
1/31/2023
Today
2/04/2023
Next Earnings (Estimated)
4/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
15,700
Year Founded
1958

Price Target and Rating

Average Stock Price Forecast
$89.74
High Stock Price Forecast
$134.00
Low Stock Price Forecast
$66.00
Forecasted Upside/Downside
+9.3%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
19 Analysts

Profitability

Net Income
$1.50 billion
Pretax Margin
32.84%

Debt

Sales & Book Value

Annual Sales
$5.38 billion
Cash Flow
$2.39 per share
Book Value
$9.39 per share

Miscellaneous

Free Float
610,284,000
Market Cap
$50.77 billion
Optionable
Optionable
Beta
1.00

Social Links


Key Executives

  • Michael A. MussallemMichael A. Mussallem
    Chairman & Chief Executive Officer
  • Bernard J. ZovighianBernard J. Zovighian
    President
  • Scott B. UllemScott B. Ullem
    Chief Financial Officer & Vice President
  • Todd J. Brinton
    Chief Scientific Officer & VP-Advanced Technology
  • Linda J. Park
    Secretary, Senior VP & Associate General Counsel













EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price forecast for 2023?

19 equities research analysts have issued twelve-month price objectives for Edwards Lifesciences' shares. Their EW share price forecasts range from $66.00 to $134.00. On average, they expect the company's share price to reach $89.74 in the next twelve months. This suggests a possible upside of 9.3% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2023?

Edwards Lifesciences' stock was trading at $74.61 at the beginning of the year. Since then, EW shares have increased by 10.1% and is now trading at $82.12.
View the best growth stocks for 2023 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 13,930,000 shares, a decrease of 9.2% from the December 31st total of 15,340,000 shares. Based on an average daily volume of 5,170,000 shares, the days-to-cover ratio is currently 2.7 days. Approximately 2.3% of the company's stock are short sold.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) issued its earnings results on Tuesday, January, 31st. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.03. The medical research company earned $1.35 billion during the quarter, compared to analyst estimates of $1.33 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 26.05% and a net margin of 28.27%. The company's revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.51 EPS.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Edwards Lifesciences's stock split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY23 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of $2.45-$2.60 for the period, compared to the consensus EPS estimate of $2.50. The company issued revenue guidance of $5.60-$6.0 billion, compared to the consensus revenue estimate of $5.78 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (1.24%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), DekaBank Deutsche Girozentrale (0.24%), New York State Common Retirement Fund (0.20%), Bank of Montreal Can (0.20%) and CCLA Investment Management (0.17%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $82.12.

How much money does Edwards Lifesciences make?

Edwards Lifesciences (NYSE:EW) has a market capitalization of $50.77 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.44 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

The company employs 15,700 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 2/4/2023 by MarketBeat.com Staff